As Johnson & Johnson (J&J) (JNJ) approaches its upcoming Q1 earnings report on April 14, investors are once again wondering whether this healthcare giant still deserves a place in a long-term portfolio. Known for its resilience, diversified business model, and unmatched six-decade dividend streak, Johnson & Johnson enters 2026 with strong momentum. Furthermore, its 2026 growth outlook is tied to a wave of new drug approvals that could meaningfully expand its revenue base over the next few years.
JNJ stock is up 15% year-to-date (YTD), outperforming the S&P 500 Index ($SPX) dip of 0.11%. Should you grab this growth and income stock now?
